- Home
- CMMB vs SONN Comparison
CMMB vs SONN Comparison
Compare CMMB & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- SONN
- Stock Information
- Founded
- CMMB 2004
- SONN N/A
- Country
- CMMB Israel
- SONN United States
- Employees
- CMMB N/A
- SONN N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- SONN Health Care
- Exchange
- CMMB Nasdaq
- SONN Nasdaq
- Market Cap
- CMMB 22.0M
- SONN 21.4M
- IPO Year
- CMMB N/A
- SONN N/A
- Fundamental
- Price
- CMMB $2.83
- SONN $5.54
- Analyst Decision
- CMMB Strong Buy
- SONN Strong Buy
- Analyst Count
- CMMB 2
- SONN 1
- Target Price
- CMMB $26.50
- SONN $20.00
- AVG Volume (30 Days)
- CMMB 141.5K
- SONN 960.3K
- Earning Date
- CMMB 11-13-2025
- SONN 08-13-2025
- Dividend Yield
- CMMB N/A
- SONN N/A
- EPS Growth
- CMMB N/A
- SONN N/A
- EPS
- CMMB N/A
- SONN N/A
- Revenue
- CMMB N/A
- SONN $1,000,000.00
- Revenue This Year
- CMMB N/A
- SONN $5,376.22
- Revenue Next Year
- CMMB N/A
- SONN N/A
- P/E Ratio
- CMMB N/A
- SONN N/A
- Revenue Growth
- CMMB N/A
- SONN 1689.52
- 52 Week Low
- CMMB $2.71
- SONN $1.08
- 52 Week High
- CMMB $9.84
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- CMMB 21.60
- SONN 68.98
- Support Level
- CMMB $2.96
- SONN $2.71
- Resistance Level
- CMMB $3.09
- SONN $6.65
- Average True Range (ATR)
- CMMB 0.21
- SONN 0.67
- MACD
- CMMB 0.00
- SONN 0.28
- Stochastic Oscillator
- CMMB 11.26
- SONN 71.83
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.